<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706391</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100219</org_study_id>
    <nct_id>NCT03706391</nct_id>
  </id_info>
  <brief_title>Study of ALS Reversals 4: LifeTime Exposures</brief_title>
  <acronym>StARLiTE</acronym>
  <official_title>Study of ALS Reversals 4: LifeTime Exposures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National ALS Registry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Toxic Substances and Disease Registry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: There exists patients who have met ALS or PMA diagnostic criteria and
      subsequently experienced robust and sustained improvement, i.e. a &quot;reversal.&quot; Thirty-eight of
      these patients were identified in the prior Duke University study, Documentation of Known ALS
      Reversals (St.A.R. Protocol 1, Duke IRB Pro00076395). The investigators hypothesize these
      patients have had different environmental exposures than patients with typically progressive
      ALS. Identification of specific environmental influences may point to exposures which are
      protective or exposure that lead to the development of a rare and novel reversible ALS-like
      disease.

      Objective: This study seeks to identify environmental exposures associated with ALS
      reversals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that typically
      causes rapidly progressive muscle weakness, disability and premature death. In spite of a
      large number of attempted ALS trials, there are no significant disease-modifying therapies
      for this condition to-date.

      There exists a small group of patients who meet diagnostic criteria for ALS or progressive
      muscular atrophy (PMA), progress for a period of time, and then significantly improve. Some
      of these &quot;ALS reversals&quot; even make a complete recovery back to normal neurological function.
      The investigators have independently verified 38 of these cases so far through review of
      medical records and peer-reviewed literature. These patients are different in their
      demographics and disease characteristics as compared to patients with more typically
      progressive ALS.

      One possible explanation for these cases is that these patients have had protective
      environmental exposures. Another possible explanation is that these patients have had unique
      environmental exposures that led to a reversible form of ALS. Study of these selected
      reversal patients may yield valuable clues to environmental mechanisms of ALS resistance.

      This is a pilot case-control study attempting to discover environmental exposure correlates
      to ALS reversals. The investigators will recruit and enroll ALS reversal &quot;cases&quot; to fill out
      an online survey form about their life. Topics include demographics, employment history,
      military service, substance use, physical activity, family medical history, disease
      progression, residential history, occupational exposures, home exposures, hobby exposures,
      hormonal and reproductive history (female identifying subjects only), caffeine, head and neck
      injuries, electrical shocks, health insurance, subjective perception of the etiology of ALS,
      and clinical features of disease. &quot;Control&quot; participant data will come from a pre-existing
      database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Life Time Environmental Exposures</measure>
    <time_frame>2 hours to fill out survey</time_frame>
    <description>Case-control analysis of differences in environmental exposures over life time of subject. Environmental exposures will be measured with the National ALS Registry survey. Cases are &quot;ALS Reversals.&quot; Controls are typically progressive patients with ALS.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>ALS and PMA Reversals</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the cohort of subjects (38 to-date) who participated in
        the Documentation of Known ALS Reversals (Duke IRB Pro00076395) protocol and were
        subsequently thought to have an ALS Reversal.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in Documentation of Known ALS Reversals (Duke IRB Pro00076395)

          -  Confirmation of ALS or PMA (primary muscular atrophy) diagnosis through medical record
             review (previously documented in Documentation of Known ALS Reversals protocol)

          -  Sustained, robust improvement on at least one objective ALS outcomes measure (ex.
             ALSFRS-R, FVC, strength testing, EMG) (previously documented in Documentation of Known
             ALS Reversals protocol)

          -  Able to understand English

        Exclusion Criteria:

          -  History of cognitive impairment severe enough to preclude informed consent, reported
             by patient on direct questioning or as suspected by research personnel from
             Documentation of Known ALS Reversals (Duke IRB Pro00076395) study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Duke ALS Clinic / DUSOM Dept of Neurology / DUHS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>ALSUntangled Group. ALSUntangled No. 12: Dean Kraft, Energy Healer. Amyotroph Lateral Scler. 2011 Sep;12(5):389-91. doi: 10.3109/17482968.2011.609309.</citation>
    <PMID>21981685</PMID>
  </reference>
  <reference>
    <citation>Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, Cudkowicz M, Sherman A. How common are ALS plateaus and reversals? Neurology. 2016 Mar 1;86(9):808-12. doi: 10.1212/WNL.0000000000002251. Epub 2015 Dec 9.</citation>
    <PMID>26658909</PMID>
  </reference>
  <reference>
    <citation>http://www.wsj.com/articles/the-mystery-of-als-patients-who-see-improvement-1465845332</citation>
  </reference>
  <reference>
    <citation>Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, van den Berg LH, Crayle J, Bedlack R; Pooled Resource Open-Access ALS Clinical Trials Consortium. &quot;ALS reversals&quot;: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):495-499. doi: 10.1080/21678421.2018.1457059. Epub 2018 Apr 2.</citation>
    <PMID>29607695</PMID>
  </reference>
  <reference>
    <citation>Crayle J and Bedlack R. Unpublished data. 2018.</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>progressive muscular atrophy</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>ALS Reversal</keyword>
  <keyword>PMA Reversal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

